Darwin AG: Preliminary group sales confirm positive development; strong growth expected for 2025

Munich February 12, 2025 (pta016/12.02.2025/10:00 UTC+1)

Darwin AG (ISIN DE000A3C35W0) generated group sales of around €28 million (previous year: around €18 million) in the 2024 financial year based on preliminary financial figures. This corresponds to sales growth of above 50% compared to the same period last year.

For the 2025 financial year, the Management Board expects sales growth of above 100% compared to 2024 and thus group sales of more than €56 million.

"We are very satisfied with the development of group sales in the 2024 financial year," commented CEO Dr. Daniel Wallerstorfer. "The very positive outlook for 2025 shows that we can grow dynamically in a difficult market environment and will exploit our potential even further in the future," continued the company founder and board member.

The publication of the audited group figures is planned for mid-May 2025.

Background

The "Darwin Group" (i.e. Darwin AG including its subsidiaries), headquartered in Munich (Germany), is a European biotechnology company, particularly in the field of human genetics. The genetic analyzes carried out in our own laboratory are used in diagnostics, therapy and prevention of diseases as well as in the production of individually designed nutritional supplements and cosmetics. Darwin also acts as a partner for doctors, therapists, pharmacists, nutritionists or fitness trainers and, by analyzing the respective genetic predisposition of the patient or customer, helps to ensure the best possible treatment or care for their needs. Darwin also invests in innovative companies in the biotech, healthcare and life sciences sectors.

(end)

Emitter:	Darwin AG Brienner Straße 7 80333 München Germany
Contact Person:	Daniel Wallerstorfer
Phone:	+49 89 20 500 450
E-Mail:	investor.relations@darwin-biotech.com
Website:	www.darwin-biotech.com
ISIN(s):	DE000A3C35W0 (Share)
Stock Exchange(s):	Free Market in Frankfurt, Munich (m:access)